Literature DB >> 30385466

Reporting harms more transparently in trials of cancer drugs.

Bishal Gyawali1, Tomoya Shimokata1, Kazunori Honda2, Yuichi Ando1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30385466     DOI: 10.1136/bmj.k4383

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  7 in total

Review 1.  Mitigating acute chemotherapy-associated adverse events in patients with cancer.

Authors:  Nicole M Kuderer; Aakash Desai; Maryam B Lustberg; Gary H Lyman
Journal:  Nat Rev Clin Oncol       Date:  2022-10-11       Impact factor: 65.011

2.  Olaparib treatment in older patients with ovarian cancer: need for 'real-world' data beyond clinical trials.

Authors:  Gabor Liposits; Christian Nielsen Wulff; Anne Otland; Lars Ulrik Fokdal
Journal:  Ecancermedicalscience       Date:  2020-09-15

3.  Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals.

Authors:  Myung Sun Kim; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03

4.  Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Authors:  Huseyin Naci; Courtney Davis; Jelena Savović; Julian P T Higgins; Jonathan A C Sterne; Bishal Gyawali; Xochitl Romo-Sandoval; Nicola Handley; Christopher M Booth
Journal:  BMJ       Date:  2019-09-18

5.  Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis.

Authors:  Sergio Modafferi; Markus Ries; Vittorio Calabrese; Claus P Schmitt; Peter Nawroth; Stefan Kopf; Verena Peters
Journal:  Diabetes Ther       Date:  2019-01-07       Impact factor: 2.945

6.  'The same old story': thoughts on authorized doses of anticancer drugs.

Authors:  Fausto Meriggi; Alberto Zaniboni
Journal:  Ther Adv Med Oncol       Date:  2020-02-22       Impact factor: 8.168

7.  Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial.

Authors:  Tom Treasure; Vern Farewell; Fergus Macbeth; Kathryn Monson; Norman R Williams; Chris Brew-Graves; Belinda Lees; Olivia Grigg; Lesley Fallowfield
Journal:  Trials       Date:  2019-12-12       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.